Leukemia Clinical Trial
Official title:
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Verified date | May 2022 |
Source | University Hospital Schleswig-Holstein |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Rationale/Purpose: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia (ALL). This trial is studying several different combination chemotherapy regimens to compare how well they work in treating young patients with ALL. Study objectives Primary study questions: - Non high-risk (non-HR) precursor-B ALL (pB-ALL) patients with TEL/AML1-negative ALL or unknown TEL/AML1 status and flow cytometry minimal residual disease (MRD) in bone marrow on day 15 <0.1% or with TEL/AML1-positive ALL (randomized study question R1): Can the daunorubicin dose in Protocol IA be safely reduced by 50 % with a non-inferior EFS and a reduction of toxicity (treatment-related mortality and AE/SAE in Protocol I)? - Patients with pB-ALL and risk group medium risk (MR) (randomized study question R2): Can the clinical outcome be improved by protracted asparagine depletion achieved through application of intensified PEG-L-asparaginase during reintensification and early maintenance? - High-risk (HR) patients (as identified by day 33 - randomized study question RHR): Can the clinical outcome be improved by protracted exposure to PEG-L-asparaginase during Protocol IB? Secondary study questions: - Standard risk (SR) patients identified by at least one sensitive marker: Is the clinical outcome comparable to that obtained in SR patients (identified with two sensitive markers) in AIEOP-BFM ALL 2000, or can the outcome even be improved with the use of PEG-L-asparaginase instead of native E. coli L-ASP? - T-ALL non-HR patients: Can the high level of outcome which was obtained for these patients in study AIEOP-BFM ALL 2000 be preserved or even improved with the use of PEG-L-ASP instead of native E. coli L-ASP? - HR patients with persisting high MRD levels despite the use of the HR blocks in the intensified consolidation phase "MRD Non-Responders": Is it possible to improve the outcome and to achieve a further reduction of leukemic cell burden by administration of an innovative treatment schedule (DNX-FLA)? - Patients participating in the randomized asparaginase studies (pB-ALL/MR, HR): Are asparaginase activity and asparaginase antibodies associated with development of allergic reactions, and do they have an effect on the outcome of the patients? - What is the relative value of different methods of MRD monitoring in the definition of alternative stratification systems within a BFM-oriented protocol?
Status | Completed |
Enrollment | 6136 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 18 Years |
Eligibility | Inclusion Criteria: - newly diagnosed acute lymphoblastic leukemia - age = 1 year (> 365 days) and < 18 years old (up to 17 years old and 365 days) - no Ph+ (BCR/ABL or t(9;22)-positive) ALL - no evidence of pregnancy or lactation period - no participation in another clinical study - patient enrolled in a participating center - written informed consent Exclusion Criteria: - pre-treatment with cytostatic drugs - pre-treatment with cytostatic drugs - steroid pre-treatment with = 1 mg/kg/d for more than two weeks during the last month before diagnosis - treatment started according to another protocol - underlying diseases that prohibit treatment according to the protocol - ALL diagnosed as second malignancy steroid pre-treatment with = 1 mg/kg/d for more than two weeks during the last month before diagnosis |
Country | Name | City | State |
---|---|---|---|
Australia | The Sydney Children's Hospital, Centre for Children's Cancer and Blood Disorders | Randwick | |
Australia | The Children's Hospital at Westmead, Department of Oncology | Westmead | |
Austria | Krankenhaus Dornbirn, Abt. für Kinder- und Jugendheilkunde | Dornbirn | |
Austria | Univ.-Kinderklinik Graz, Abt. Pädiatrische Hämato-Onkologie | Graz | |
Austria | Department f. Kinder- u. Jugendheilkunde, Universitätsklinik f. Pädiatrie II | Innsbruck | |
Austria | A.oe. Landeskrankenhaus Klagenfurt, Abt. für Kinder- und Jugendheilkunde | Klagenfurt | |
Austria | A.oe. Landeskrankenhaus Leoben, Abt. für Kinder und Jugendliche | Leoben | |
Austria | Landes-Kinderklinik Linz, Haematologie/Onkologie | Linz | |
Austria | St. Johanns Spital / Landeskrankenhaus, Salzburg, Kinderspital Abt. Kinder u. Jugendheilkunde | Salzburg | |
Austria | St. Anna Kinderspital, Zentrum für Kinder- und Jugendheilkunde | Wien | |
Czechia | University Hospital Brno, Department of Pediatric Oncology | Brno | |
Czechia | Regional Hospital Ceské Budejovice, Department of Pediatrics | Ceské Budejovice | |
Czechia | University Hospital Hradec Králové, Department of Pediatrics | Hradec Králové | |
Czechia | University Hospital Olomouc, Department of Pediatrics | Olomouc | |
Czechia | Teaching Hospital Ostrava-Poruba, Department of Pediatrics | Ostrava-Poruba | |
Czechia | University Hospital Plzen, Department of Pediatrics | Plzen | |
Czechia | University Hospital Motol, Department of Pediatric Hematology and Oncology | Praha 5 | |
Czechia | Masaryk´s Hospital Ústí nad Labem, Department of Pediatrics | Ústí nad Labem | |
Germany | Kinderklinik der med. Fakultät der RWTH, Bereich Hämatologie/Onkologie | Aachen | |
Germany | I. Klinik für Kinder u. Jugendliche, Klinikum Augsburg, Hämatologie/ Onkologie | Augsburg | |
Germany | Klinikum Bayreuth, Kinderklinik | Bayreuth | |
Germany | Kinderklinik der Charité, Campus Virchow Klinikum (CVK), Abt.: Kinderhämatologie | Berlin | |
Germany | Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie | Berlin | |
Germany | Städtisches Krankenhaus, Kinderklinik | Braunschweig | |
Germany | Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Hämatologie / Onkologie | Chemnitz | |
Germany | Carl-Thiem-Klinikum, Kinderklinik, Abt. Hämatologie/Onkologie | Cottbus | |
Germany | Vestische Kinder- u. Jugendklinik, Universitätsklinik Witten/Herdecke | Datteln | |
Germany | Klinikum Lippe-Detmold, Kinder- und Jugendmedizin | Detmold | |
Germany | Klinikum Dortmund, Klinik f. Kinder- und Jugendmedizin | Dortmund | |
Germany | Uni.Klinik Carl Gustav Carus, Klinik f. Kinderheilkunde | Dresden | |
Germany | Universitätskinderklinik | Düsseldorf | |
Germany | Helios Klinikum Erfurt GmbH, Klinik für Kinderheilkunde | Erfurt | |
Germany | Universitätsklinikum Erlangen, Kinder- und Jugendmedizin, Abt. für Onkologie/ Hämatologie/Immunologie | Erlangen | |
Germany | Universitätsklinikum Essen, Kinderklinik, Hämatologie/Onkologie | Essen | |
Germany | Universitäts-Kinderklinik, Klinik für Kinderheilkunde III, Pädiatrische Hämatologie/Onkologie | Frankfurt | |
Germany | Universitäts-Kinderklinik, Haematologie/ Onkologie | Freiburg | |
Germany | Klinikum der Justus-Liebig-Universität, Zentrum für Kinderheilkunde, Abt. Hämatologie/Onkologie | Gießen | |
Germany | Universitäts-Kinderklinik Päd. I, Hämatologie/Onkologie | Göttingen | |
Germany | Klinik und Poliklinik für Kinder und Jugendmedizin, Allgemeine Pädiatrie mit Poliklinik/Pädiatrische Onkologie und Hämatologie | Greifswald | |
Germany | Uniklinikum d. Martin Luther Universität, Halle Wittenberg, Univ.-und Poliklinik für Kinder- und Jugendmedizin | Halle | |
Germany | Medizinische Hochschule Hannover, Zentrum Kinderheilkunde u. Jugendmedizin | Hannover | |
Germany | Universitäts-Kinderklinik, Päd. Onkologie, Hämatologie, und Immunologie | Heidelberg | |
Germany | Klinikum Heilbronn GmbH, Klinik für Kinderheilkunde und Jugendmedizin/Perinatalzentrum | Heilbronn | |
Germany | Gemeinschaftskrankenhaus Herdecke, Kinderabteilung | Herdecke | |
Germany | Universitätsklinik für, Kinder- und Jugendmedizin, Päd. Hämatologie/ Onkologie | Homburg / Saar | |
Germany | Klinikum, der Friedrich-Schiller-Universität, Klinik für Kinder- und Jugendmedizin | Jena | |
Germany | Städtisches Klinikum Karlsruhe, Kinderklinik | Karlsruhe | |
Germany | Klinikum Kassel, Kinderklinik | Kassel | |
Germany | Klinik für Allgemeine Paediatrie, Univ.-Klinikum Schleswig-Holstein, Campus Kiel | Kiel | |
Germany | Städtisches Krankenhaus Kemperhof, Kinderklinik | Koblenz | |
Germany | Kliniken der Stadt Köln GmbH, Kinderkrankenhaus Riehl | Köln | |
Germany | Med. Einrichtungen der Universität zu Köln, Klinik für Allg. Kinderheilkunde, Onkologisch-hämatologische Station | Köln | |
Germany | Department für Frauen- und Kindermedizin, Abteilung für Pädiatrische Onkologie, Hämatologie und Hämostaseologie | Leipzig | |
Germany | Universität zu Lübeck, Klinik für Kinder- u. Jugendmedizin, Abt. Hämatologie/ Onkologie/Immunologie | Lübeck | |
Germany | Universitätsklinikum Magdeburg, Klinik für Päd. Hämatologie/Onkologie | Magdeburg | |
Germany | Klinikum Mannheim gGmbH, Kinderklinik, Abt. Hämatologie/Onkologie | Mannheim | |
Germany | Johannes Wesling Klinikum Minden | Minden | |
Germany | Städt. Krankenhaus München GmbH, Krankenhaus München-Schwabingen, Kinderklinik d. TU | München | |
Germany | Universitäts-Kinderklinik, Päd. Hämatologie und Onkologie | Münster | |
Germany | Cnopf'sche Kinderklinik, Onkologie | Nürnberg | |
Germany | Klinikum Oldenburg gGmbH, Zentrum für Kinder- u. Jugendmedizin, (Elisabeth Kinderkrankenhaus) | Oldenburg | |
Germany | Universitäts-Kinderklinik | Rostock | |
Germany | Asklepios-Klinik, Sankt Augustin GmbH | Sankt Augustin | |
Germany | HELIOS Kliniken Schwerin, Klinik f. Kinder-u. Jugendmedizin | Schwerin | |
Germany | Olga-Hospital, Kinderklinik, Pädiatrisches Zentrum, Abt. Hämatologie/Onkologie | Stuttgart | |
Germany | Krankenanstalt Trier, Mutterhaus der Borromaeerinnen, Pädiatrische Abteilung | Trier | |
Germany | Universitäts-Kinderklinik, Abt. Kinderheilkunde II, Hämatologie/Onkologie | Tübingen | |
Germany | Universitäts-Kinderklinik | Ulm | |
Germany | Stadtkrankenhaus, Kinderklinik | Wolfsburg | |
Germany | Universitäts-Kinderklinik | Würzburg | |
Israel | HaEmek Medical Center | Afula | |
Israel | Soroka Medical Center | Beer-Sheva | |
Israel | Bnai-Zion Medical Center | Haifa | |
Israel | Rambam Medical Center | Haifa | |
Israel | Hadassah University Medical Center | Jerusalem | |
Israel | Schneider Children Medical Center of Israel | Petach Tikva | |
Israel | Dana children hospital | Tel-Aviv | |
Israel | Sheba Medical Center | Tel-Hashomer | |
Italy | Centro Regionale Oncoematologia Pediatrica Ospedale dei Bambini "G. Salesi" Clinica Pediatrica | Ancona | |
Italy | Dipartimento Biomedicina Età Evolutiva U.O Pediatrica I Policlinico | Bari | |
Italy | U.O.C. Pediatria e Patologia Neonatale Ospedale San Martino | Belluno | |
Italy | U.O. Pediatrica - OO.RR Bergamo | Bergamo | |
Italy | Istituto Ortopedico Rizzoli Sez. di chemioterapia dei tumori dell'apparato locomotore | Bologna | |
Italy | Oncologia ed Ematologia "Lalla Seràgnoli" Clinica Pediatrica Policlinico Sant'Orsola Malpighi | Bologna | |
Italy | Pediatria Ospedale Regionale | Bolzano | |
Italy | Clinica Pediatrica Oncoematologia pediatrica e TMO Ospedale dei Bambini | Brescia | |
Italy | Istituto di Clinica Pediatrica Ospedale Regionale per le Microcitemie | Cagliari | |
Italy | Divisione Ematologia - Oncologia Pediatrica Clinica Pediatrica | Catania | |
Italy | Unità Operativa di Ematologia ed Oncologia Pediatrica Az. Osp. "Pugliese-Ciaccio" | Catanzaro | |
Italy | Unità Operativa Pediatria Azienda Ospedaliera Annuziata | Cosenza | |
Italy | Dipartimento di Medicina Clinica e Sperimentale Sezione di Pediatria Università di Ferrara | Ferrara | |
Italy | Dipartimento A.I. Oncoematologia Pediatrica e Cure Domiciliari U.O. Oncoematologia Pediatrica Azienda Ospedaliero-Universitaria Meyer | Firenze | |
Italy | Dipartimento di Ematologia e Oncologia Pediatrica Instituto " G. Gaslini" | Genova | |
Italy | Ospedale "Vito Fazzi" U.O. di Pediatria | Lecce | |
Italy | Clinica Pediatrica II De Marchi | Milano | |
Italy | Divisione di Oncologia Pediatrica Ist. Nazionale Studio e Cura Tumori | Milano | |
Italy | Divisione Pediatria "Mariani" Ospedale "Niguarda Ca' Granda" | Milano | |
Italy | Unità di Ricerca Clinica Pediatrica HSR TIGET - Istituto Scientifico San Raffaele | Milano | |
Italy | U.O. di Ematologia, oncologia e trapianto Azienda Policlinico di Modena | Modena | |
Italy | Clinica Pediatrica dell'Università Milano - Bicocca A.O. San Gerardo - Fondazione MBBM | Monza | |
Italy | A.O. "A. Cardarelli", U.O.S. Talassemia pediatrica ed emoglobinopatie pediatriche | Napoli | |
Italy | Dipartimento di Oncologia A.O. Santobono - Pausilipon | Napoli | |
Italy | Servizio di Oncologia Pediatrica Dipartimento di Pediatria Seconda Università degli Studi di Napoli | Napoli | |
Italy | U.O.C. Pediatria - TIN, Ospedale "Umberto Primo" ASL SA - 1 | Nocera Inferiore | |
Italy | S.C.D.U. Azienda Ospedaliera "Maggiore della carità" | Novara | |
Italy | Dipartimento di Pediatria Università di Padova Cattedra Di Oncoematologia Pediatrica | Padova | |
Italy | Oncoematologia Pediatrica Ospedale dei Bambini G. di Cristina | Palermo | |
Italy | U.O. di Pediatria e Oncoematologia Pediatrica Az. Osp. Di Parma Ospedali Riuniti | Parma | |
Italy | Oncoematologia Pediatrica IRCCS, Policlinico San Matteo | Pavia | |
Italy | S.C. di Oncoematologia Pediatrica con Trapianto di CSE, Ospedale "S.M. della Misericordia" A.O. Perugia | Perugia | |
Italy | Ematologia, Ospedale di Muraglia | Pesaro | |
Italy | U.O. Pediatrica Azienda Ospedaliera San Salvatore | Pesaro | |
Italy | Dipartimento di Ematologia Ospedale Civile | Pescara | |
Italy | Centro di Oncoematologia Pediatrica e Trapianto Midollo Osseo Azienda Ospedaliero Universitaria Pisana Ospedale S. Chiara | Pisa | |
Italy | Centro Integrato di Emato-oncologia e dell'adolescenza A.O. S. Maria degli Angeli - Pordenone e IRCCS Centro di Riferimento Oncologico - Aviano | Pordenone | |
Italy | Divisione Ematologia Ospedali Riuniti | Reggio Calabria | |
Italy | U.O Pediatria Ospedale Infermi Azienda USL Rimini | Rimini | |
Italy | Divisione di Ematologia Pediatrica Ospedale "Bambin Gesù"Istituto di Ricerca Scientifica | Roma | |
Italy | Divisione Oncologia Pediatrica Ospedale "Bambin Gesù" | Roma | |
Italy | Divisione Oncologia Pediatrica Università Cattolica di Roma | Roma | |
Italy | Oncoematologia pediatrica Università "La Sapienza" Roma | Roma | |
Italy | Ospedale Sant'Eugenio clinica pediatrica Univ. Tor Vergata | Roma | |
Italy | Sezione Ematologia Dipart. di biotecnologie Cellulari ed Ematologia Università "La Sapienza" | Roma | |
Italy | U.O. Oncoematologia Pediatrica Ospedale "Casa Sollievo della Sofferenza" | San Giovanni Rotondo | |
Italy | Clinica Pediatrica Università | Sassari | |
Italy | Dipartimento di Pediatria Ostetricia e Medicina della Riproduzione Università degli Studi di Siena | Siena | |
Italy | Ospedale Infantile Regina Margherita | Torino | |
Italy | Unità Operativa di Pediatria - U.T.I.N. Az.Osp. "Card. G. Panico" | Tricase | |
Italy | U.O. Emato-Oncologia Pediatrica Università degli studi di Trieste Ospedale Infantile Burlo Garofolo | Trieste | |
Italy | SOS Oncologia Pediatrica Policlinico Universitario | Udine | |
Italy | Clinica Pediatrica Università degli Studi dell'Insubria di Varese Ospedale "Filippo del Ponte" | Varese | |
Italy | U.O.C Oncoematologia Pediatrica Policlinico "G.B: Rossi" | Verona | |
Italy | Ospedale San Bortolo, U.O. di Pediatria e patologia Neonatale | Vicenza | |
Switzerland | Kinderklinik, Hämatologie/Onkologie | Aarau | |
Switzerland | Baseler Kinderspital, Hämatologische Poliklinik | Basel | |
Switzerland | Repartio di Pediatria | Bellinzona | |
Switzerland | Pädiatrische Klinik, Kinderspital Luzern, Kinderonkologie | Luzern | |
Switzerland | Hämatologie/Onkologie, Ostschweizer Kinderspital, FMH Pädiatrie, Hämatologie | St. Gallen | |
Switzerland | Kinderspital Zürich, Universitäts-Kinderklinik | Zürich |
Lead Sponsor | Collaborator |
---|---|
University Hospital Schleswig-Holstein | Deutsche Krebshilfe e.V., Bonn (Germany) |
Australia, Austria, Czechia, Germany, Israel, Italy, Switzerland,
Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, Aricò M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010 Apr 22;115(16):3206-14. doi: 10.1182/blood-2009-10-248146. Epub 2010 Feb 12. — View Citation
Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR; International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008 Apr;22(4):771-82. doi: 10.1038/leu.2008.5. Epub 2008 Jan 31. — View Citation
Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010 Feb;24(2):265-84. doi: 10.1038/leu.2009.257. Epub 2009 Dec 10. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Event-free survival | Randomization R1: Event-free survival from time of randomization
Historical comparison non-HR T-ALL: Event-free survival from diagnosis Historical comparison "MRD Non-Responders": Event-free survival from start of DNX-FLA (morphological non-response after HR-3' is no event for this study question) |
10 years from the start of recruitment | |
Primary | Disease-free survival | Randomization R2: Disease-free survival from time of randomization
Historical comparison SR: Disease-free survival from start of Protocol M |
10 years from the start of recruitment | |
Primary | minimal residual disease (MRD) | Randomization RHR: rate of MRD highly positive patients (MRD = 10-3) at TP2 (week 12) | week 12 of treatment | |
Secondary | survival | All randomized and historical comparisons: Survival | 10 years from the start of recruitment | |
Secondary | treatment-related mortality | All randomized and historical comparisons: treatment-related mortality in induction or CCR (overall and by chemotherapy/SCT) | up to 25 months from the diagnosis | |
Secondary | adverse events | All randomized and historical comparisons: incidence and frequency of adverse events of interest and serious adverse events | up to 25 months from the diagnosis | |
Secondary | event-free survival | Randomization R-HR: Event-free survival from time of randomization | 10 years from the start of recruitment | |
Secondary | minimal residual disease | "MRD Non-Responders": MRD levels after DNX-FLA | after 24 weeks of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |